Stifel lowered the firm’s price target on Elanco (ELAN) to $13 from $15 and keeps a Buy rating on the shares following survey work focused on recent innovation from the major Animal Health players.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco Animal Health: Strong Buy Rating Driven by Pet Health Growth and Innovative Products
- Elanco Animal Health Announces Board Changes Amid New Agreement
- Elanco director buys $272.6K in common stock
- Elanco price target lowered to $12 from $16 at Piper Sandler
- Elanco Animal Health: Undervalued Growth Potential with Strong Product Performance and Debt Reduction